Allergy and Immunology, Allergy · Portsmouth, NH
NPI
1982601084
Since 2005
Specialty
Allergy and Immunology, Allergy
Code 207KA0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
100 Griffin Rd, Unit A
Portsmouth, NH, 03801
Phone (603) 436-7897
Groups this clinician bills Medicare through
Medicare paid, 2024
$54K
3,801 services
Medicare patients, 2024
300
Average age 72
Drug cost, 2024
$513K
1,102 prescriptions
Company payments, 2025
$468
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin J Roelofs was code 95004 (test - miscellaneous), 2,049 times for 66 patients. In total Kevin J Roelofs billed 3,801 services in 24 codes, and Medicare paid $54K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 2,049 | 66 | $2.70 | $5,532 |
| 95165 Treatment - Miscellaneous | Office | 480 | 14 | $11.64 | $5,586 |
| 95117 Treatment - Miscellaneous | Office | 266 | 79 | $9.19 | $2,444 |
| 99214 Office E&M - Established | Office | 167 | 115 | $87.73 | $15K |
| 94010 Pulmonary Function Testing | Office | 161 | 116 | $20.28 | $3,266 |
| 95024 Test - Miscellaneous | Office | 152 | 25 | $5.35 | $814 |
| 99213 Office E&M - Established | Office | 82 | 74 | $71.02 | $5,823 |
| 95115 Treatment - Miscellaneous | Office | 55 | 18 | $7.43 | $409 |
| 99203 Office E&M - New | Office | 50 | 50 | $73.54 | $3,677 |
| 99204 Office E&M - New | Office | 37 | 37 | $131.65 | $4,871 |
| 94060 Pulmonary Function Testing | Office | 12 | 12 | $29.35 | $352 |
By year: 2022 $51K for 2,918 services; 2023 $49K for 3,154 services; 2024 $54K for 3,801 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kevin J Roelofs prescribed most often to Medicare patients was Montelukast Sodium, with 163 prescriptions and refills. In total Kevin J Roelofs wrote 1,102 Medicare prescriptions that cost $513K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 163 | 377 | 42 | $2,594 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 108 | 143 | 55 | $2,839 |
| Fluticasone Propionate Generic | 100 | 152 | 30 | $1,109 |
| Azelastine Hcl Generic | 76 | 127 | 33 | $4,013 |
| Olopatadine Hcl Generic | 67 | 126 | 27 | $7,866 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 59 | 79 | 17 | $9,482 |
| Symbicort Budesonide/Formoterol Fumarate | 49 | 100 | 21 | $21K |
| Breyna Budesonide/Formoterol Fumarate | 38 | 54 | 14 | $5,910 |
| Breo Ellipta Fluticasone/Vilanterol | 37 | 57 | Under 11 | $22K |
| Mometasone Furoate Generic | 31 | 54 | Under 11 | $4,081 |
| Advair Hfa Fluticasone Propion/Salmeterol | 30 | 35 | Under 11 | $11K |
| Dupixent Pen Dupilumab | 27 | 32 | Under 11 | $121K |
| Arnuity Ellipta Fluticasone Furoate | 27 | 35 | Under 11 | $6,756 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 24 | 24 | Under 11 | $48K |
| Ventolin Hfa Albuterol Sulfate | 22 | 27 | Under 11 | $1,431 |
Brand drugs: 430 claims; generic drugs: 672 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin J Roelofs $468 ($468 in general payments such as food, travel and fees) from 9 companies. The largest payer was Genzyme Corporation with $174.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 12 | $174 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $50.8 |
| Pharming Healthcare, Inc. | 2 | $50.31 |
| Blueprint Medicines Corporation SNY | 1 | $42.43 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $40.98 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $38.44 |
| CSL Behring CSL.AX | 1 | $26.03 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 1 | $23.79 |
| Grifols USA, LLC | 1 | $21 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.